The San Francisco-based biopharmaceutical company, CymaBay Therapeutics, focuses on developing breakthrough medicines for important human diseases. With a robust pipeline, their novel oral small molecule, arhalofenate, shows promise in reducing gout flares while simultaneously lowering uric acid levels. This unique dual-action profile sets it apart from other urate lowering therapies. CymaBay Therapeutics also specializes in the discovery and development of proprietary medicines for metabolic diseases, particularly type 2 diabetes. Their rich pipeline includes four clinical-stage compounds, including MBX-102/JNJ 39659100, which has recently completed a Phase 2/3 trial. Additionally, they are dedicated to providing innovative therapies for patients with liver and other chronic diseases, with seladelpar being developed for the treatment of primary biliary cholangitis.